Cantor Fitzgerald Reaffirms Overweight Rating for Novo Nordisk A/S (NYSE:NVO)

Cantor Fitzgerald restated their overweight rating on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $140.00 target price on the stock. A number of other analysts have also commented on the company. UBS Group began coverage on Novo Nordisk […]

Related Keywords

Taiwan ,United States ,China ,Hong Kong ,America ,Novo Nordisk ,Ieq Capital ,Cantor Fitzgerald ,Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet ,Morgan Stanley ,Green Square Capital Advisors ,Benedict Financial Advisors Inc ,Free Report ,Moderate Buy ,Hishtalmut Le Morim Tichoniim Havera Menahelet ,Financial Advisors ,Square Capital Advisors ,Get Free Report ,Middle East ,Mainland China ,North America ,Obesity Care ,Novo Nordiska S ,Nyse Nvo ,Nvo ,Medical ,Reiterated Rating ,